Efficacy and safety of antiretroviral therapy in «naive» patients with late stage of HIV infection
- Authors: Veselova E.I.1, Karamov E.V.1, Kudlay D.A.2,3, Samoilova A.G.1, Kaminsky G.D.1
-
Affiliations:
- Scientific Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Healthcare of Russia
- State Research Center «Institute of Immunology» of FMBA
- I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
- Issue: Vol 8, No 3 (2022)
- Pages: 27-34
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288915
- DOI: https://doi.org/10.18565/therapy.2022.3.27-34
- ID: 288915
Cite item
Abstract
Full Text
About the authors
Elena I. Veselova
Scientific Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Healthcare of Russia
Email: drveselovae@mail.ru
researcher at the Scientific Department of infectious pathology
Eduard V. Karamov
Scientific Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Healthcare of Russia
Email: karamov2004@yandex.ru
Dr. med. habil., professor, chief researcher at the Scientific Department of infectious pathology
Dmitry A. Kudlay
State Research Center «Institute of Immunology» of FMBA; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Email: d624254@gmail.com
Dr. med. habil., professor, chief researcher at the Laboratory of personalized medicine and molecular immunology No. 71
Anastasia G. Samoilova
Scientific Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Healthcare of Russia
Email: a.samoilova.nmrc@mail.ru
Dr. med. habil., first deputy director
Grigory D. Kaminsky
Scientific Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Healthcare of Russia
Email: gregkaminski.gk@gmail.com
Dr. med. habil., head the Scientific Department of infectious pathology
References
- Regazzi M., Carvalho A.C., Villani P., Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: Focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014; 53(6): 489-507. https://dx.doi.org/10.1007/s40262-014-0144-3.
- Djimeu E.W., Heard A.C. Treatment of HIV among tuberculosis patients: A replication study of timing of antiretroviral therapy for HIV-1-associated tuberculosis. PLoS One. 2019; 14(2): e0210327. https://dx.doi.org/10.1371/journal.pone.0210327.
- Kanters S., Vitoria M., Doherty M. et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic re-view and network meta-analysis. Lancet HIV. 2016; 3(11): e510-e520. https://dx.doi.org/10.1016/S2352-3018(16)30091-1.
- Cao W., Hsieh E., Li T. Optimizing treatment for adults with HIV/AIDS in China: Successes over two decades and remaining challenges. Curr HIV/AIDS Rep. 2020; 17(1): 26-34. https://dx.doi.org/10.1007/s11904-019-00478-x.
- Rizzardo S., Lanzafame M., Lattuada E. et al. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naive patients with HIV-1 infection: an observational, retrospective, multicentre study. Int J. STD AIDS. 2019; 30(5): 467-71. https://dx.doi.org/10.1177/0956462418817049.
- Hosoda T., Uehara Y., Naito T. An HIV-infected patient with no serious adverse events after overdosing on raltegravir. Intern Med. 2020; 59(2): 285-87. https://dx.doi.org/10.2169/internalmedicine.3498-19.
- Floris-Moore M.A., Mollan K., Wilkin A.M. et al. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther. 2016; 21(1): 55-64. https://dx.doi.org/10.3851/IMP2982.
- World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. March 2021. URL: https://www.who.int/publications/i/item/9789240022232 (date of access - 02.04.2022).
- Le M.P., Valantin M.A., Assoumou L. et al. Lack of a clinically significant pharmacokinetic interaction between etravirine and raltegravir using an original approach based on drug metabolism, protein binding, and penetration in seminal fluid: A pharmacokinetic substudy of the ANRS-163 ETRAL study. Pharmacotherapy. 2019; 39(4): 514-20. https://dx.doi.org/10.1002/phar.2242.
- Mussini C., Lorenzini P., Cozzi-Lepri A. et al. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study. BMC Med. 2018; 16(1): 79. https://dx.doi.org/10.1186/s12916-018-1046-2.
- Cahn P., Rolon M.J., Figueroa M.I. et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J. Int AIDS Soc. 2017; 20(1): 21678. https://dx.doi.org/10.7448/IAS.20.01.21678.
- Libre J.M., Hung C.C., Brinson C. et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018; 391(10123): 839-49. https://dx.doi.org/10.1016/S0140-6736(17)33095-7.
- Aaron L., Saadoun D., Calatroni I. et al. Tuberculosis in HIV-infected patients: A comprehensive review. Clin Microbiol Infect. 2004; 10(5): 388-98. https://dx.doi.org/10.1111/j.1469-0691.2004.00758.x.